Is PhaseBio Pharmaceuticals Inc (PHAS) a Smart Choice in Biotechnology Monday?

Monday, October 31, 2022 11:04 AM | InvestorsObserver Analysts

Mentioned in this article

Is PhaseBio Pharmaceuticals Inc (PHAS) a Smart Choice in Biotechnology Monday?

The 43 rating InvestorsObserver gives to PhaseBio Pharmaceuticals Inc (PHAS) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 33 percent of stocks in the Biotechnology industry, PHAS’s 43 overall rating means the stock scores better than 43 percent of all stocks.

PHAS has an Overall Score of 43. Find out what this means to you and get the rest of the rankings on PHAS!

See Full PHAS Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With PhaseBio Pharmaceuticals Inc Stock Today?

PhaseBio Pharmaceuticals Inc (PHAS) stock is up 4.86% while the S&P 500 is lower by -0.63% as of 10:55 AM on Monday, Oct 31. PHAS has gained $0.01 from the previous closing price of $0.11 on volume of 1,792,445 shares. Over the past year the S&P 500 is lower by -15.98% while PHAS is lower by -97.22%. PHAS lost -$2.13 per share the over the last 12 months. Click Here to get the full Stock Report for PhaseBio Pharmaceuticals Inc stock.